Chromatin accessibility of GC- and ASC-promoting genes is regulated by SMARCA5. (A) MA plot of the log average (A) on the X-axis, and log ratio (M) on the Y-axis representing the changes in accessibility peaks under SMARCA5 deficiency (left); GO term biological pathway analysis of genes associated with differential accessibility peaks (right) upregulated in either control or Smarca5-deficient transferred B1-8^hi B cells, 5 days after immunization. Upregulated peaks in the control B cells are marked in pink and the upregulated peaks in the Smarca5-deficient B cells are marked in blue (log₂ FC greater than or equal to ±0.3, adjusted P < 0.1). (B) Distribution of SMARCA5 accessibility peaks (ATAC-seq) and binding sites (using the CUT&RUN protocol) across genomic regions. TTS: transcription termination site. (C) Box plots representing the median, quartiles, and 5th and 95th percentiles of changes in gene expression of control compared to Smarca5-deficient B cells in genes linked to ATAC peaks or both ATAC and CUT&RUN peaks compared with total genes. P value was calculated by a two-sided Wilcoxon rank sum test. (D) UMAP projections of Multiome profiles with color coding according to the different clusters. Top and bottom UMAPs represent the control and Smarca5-deficient groups, respectively. (E) Dot plots depicting the RNA expression of selected marker genes presented by average expression and percent expression per cluster. The top and bottom plots represent the control and deficient groups, respectively. (F) Gene tracks depicting chromatin accessibility and expression of selected marker genes from specific clusters. Each track also represents the DNA binding sites of SMARCA5, as shown by CUT&RUN peaks.